Medical Services

Rare and aggressive, triple-negative breast cancer (TNBC) does not show either oestrogen receptors (ER), progesterone receptors (PR), or the HER2 protein. This feature limits treatment options and increases management difficulty since it does not react to HER2-targeted medicines or hormone therapy.
About 10–15% of all breast cancer cases are TNBC, which mostly affects younger women, especially those with a BRCA1 gene mutation or of African or Hispanic background. Especially in the first five years following treatment, it frequently develops and spreads more quickly than other breast cancers and carries a higher risk of recurrence.
Lumps, breast soreness, swelling, or changes in the skin or nipple define symptoms of different breast cancers. Imaging, biopsies, and receptor testing help to establish triple-negative status and make a diagnosis.
Among standard treatments are radiation, chemotherapy, and surgery. Particularly for those with BRCA mutations, more contemporary methods, including immunotherapy and PARP inhibitors, have shown promise.
Early identification and continuous research on focused treatments are absolutely essential given its aggressive character. For triple-negative breast cancer, knowledge of risk factors and genetic counselling can lead to early intervention plans and preventative measures.